PB 118 of 2026

National Health (Minimum Stockholding) Amendment Determination (No. 9) 2026

I, Mike Pope, as delegate of the Minister for Health and Ageing, make the following determination.

Dated 27 September 2026

Mike Pope
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Authorised Version F2026L01323 registered 30/09/2026

Authorised Version F2026L01323 registered 30/09/2026

Contents

1 Name 1
2 Commencement 1
3 Authority 1
4 Schedules 1

Schedule 1—Amendments commencing 1 October 2026 2

National Health (Minimum Stockholding) Determination 2023 *2*

Authorised Version F2026L01323 registered 30/09/2026

Authorised Version F2026L01323 registered 30/09/2026

1 Name

(1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 9) 2026*.

(2) This instrument may also be cited as PB 118 of 2026.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information

Column 1	Column 2	Column 3
Provisions	**Commencement**	**Date/Details**
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 October 2026.	1 October 2026
2. Schedule 1	1 October 2026.	1 October 2026

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Authorised Version F2026L01323 registered 30/09/2026

Schedule 1—Amendments commencing 1 October 2026

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

Aciclovir	Tablet 200 mg	Oral	ARX-ACICLOVIR	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together
Aciclovir	Tablet 800 mg	Oral	ARX-ACICLOVIR	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together

2 Schedule 1 (table)

Omit:

Allopurinol	Tablet 100 mg	Oral	APO-ALLOPURINOL	4 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together

3 Schedule 1 (table)

Omit:

Allopurinol	Tablet 300 mg	Oral	APO-ALLOPURINOL	6 months stock by reference to usual demand of both Allopurinol APOTEX and APO-ALLOPURINOL added together

insert:

Allopurinol	Tablet 300 mg	Oral	APO-ALLOPURINOL	6 months stock by reference to usual demand

4 Schedule 1 (table)

Omit:

Allopurinol	Tablet 300 mg	Oral	NOUMED ALLOPURINOL	between 1 April 2026 to 30 September 2026—0 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026

5 Schedule 1 (table)

Omit:

Amlodipine	Tablet 5 mg (as besilate)	Oral	APX-AMLODIPINE	6 months stock by reference to usual demand of both Amlodipine APOTEX and APX-AMLODIPINE added together

insert:

Amlodipine	Tablet 5 mg (as besilate)	Oral	APX-AMLODIPINE	6 months stock by reference to usual demand

6 Schedule 1 (table)

Omit:

Amoxicillin with clavulanic acid	Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Alphaclav Duo Viatris	after 31 December 2025—6 months stock by reference to usual demand of both Alphaclav Duo Viatris and AlphaClav Duo added together

insert:

Amoxicillin with clavulanic acid	Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Alphaclav Duo Viatris	6 months stock by reference to usual demand

7 Schedule 1 (table)

After:

Aripiprazole	Tablet 10 mg	Oral	APO-Aripiprazole	3 months stock by reference to usual demand

insert:

Aripiprazole	Tablet 10 mg	Oral	ARIPIPRAZOLE-WGR	Between 1 October 2026 and 28 February 2027—0 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026

8 Schedule 1 (table)

Omit:

Atomoxetine	Capsule 100 mg (as hydrochloride)	Oral	Atomoxetine Sandoz	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand

9 Schedule 1 (table)

Omit:

Bivalirudin	Powder for I.V. injection 250 mg (as trifluoroacetate)	Injection	BIVALIRUDIN ARX	4 months stock by reference to usual demand of both Bivalirudin APOTEX and BIVALIRUDIN ARX added together

10 Schedule 1 (table)

Omit:

Bosentan	Tablet 125 mg (as monohydrate)	Oral	Bosentan Viatris	4 months stock by reference to usual demand of both Bosentan Mylan and Bosentan Viatris added together

11 Schedule 1 (table)

After:

Captopril	Oral solution 5 mg per mL, 95 mL	Oral	Capoten	4 months stock by reference to usual PBS demand

insert:

Cefalexin	Capsule 250 mg (as monohydrate)	Oral	Keflex	Between 1 October 2026 and 31 March 2027—0 months stock by reference to usual demand

12 Schedule 1 (table)

Omit:

Erlotinib	Tablet 150 mg (as hydrochloride)	Oral	Erlotinib APOTEX	after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 150 mg (as hydrochloride)	Oral	ERLOTINIB ARX	after 30 November 2025—4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together

Authorised Version F2026L01323 registered 30/09/2026

Erlotinib	Tablet 25 mg (as hydrochloride)	Oral	Erlotinib APOTEX	4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together
Erlotinib	Tablet 25 mg (as hydrochloride)	Oral	ERLOTINIB ARX	4 months stock by reference to usual demand of both ERLOTINIB ARX and Erlotinib APOTEX added together

13 Schedule 1 (table)

Omit:

Fluconazole	Capsule 200 mg	Oral	APO-Fluconazole	4 months stock by reference to usual demand of both Fluconazole APOTEX and APO-Fluconazole added together

14 Schedule 1 (table)

After:

Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand

insert:

Glibenclamide	Tablet 5 mg	Oral	Daonil	Between 1 October 2026 and 31 May 2027—0 months stock by reference to usual demand

15 Schedule 1 (table)

Omit:

Glimepiride	Tablet 1 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 2 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together

Authorised Version F2026L01323 registered 30/09/2026

Glimepiride	Tablet 3 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together
Glimepiride	Tablet 4 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand of both Glimepiride APOTEX and ARX-GLIMEPRIDE added together

insert:

Glimepiride	Tablet 1 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand
Glimepiride	Tablet 2 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand
Glimepiride	Tablet 3 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand
Glimepiride	Tablet 4 mg	Oral	ARX-GLIMEPIRIDE	6 months stock by reference to usual demand

16 Schedule 1 (table)

Omit:

Hydrocortisone	Injection 100 mg (as sodium succinate) with 2 mL solvent	Injection	Solu-Cortef	6 months stock by reference to usual PBS demand
Hydrocortisone	Injection 250 mg (as sodium succinate) with 2 mL solvent	Injection	Solu-Cortef	6 months stock by reference to usual PBS demand

17 Schedule 1 (table)

Omit:

Imatinib	Capsule 100 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together
Imatinib	Capsule 400 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand of both Imatinib-APOTEX and ARX-IMATINIB added together

Authorised Version F2026L01323 registered 30/09/2026

insert:

Imatinib	Capsule 100 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand
Imatinib	Capsule 400 mg (as mesilate)	Oral	ARX-IMATINIB	3 months stock by reference to usual demand

18 Schedule 1 (table)

Omit:

Lamivudine	Tablet 150 mg	Oral	Lamivudine Viatris	after 30 September 2025—4 months stock by reference to usual demand of both Lamivudine Viatris and Lamivudine Alphapharm added together

19 Schedule 1 (table)

Omit:

Leflunomide	Tablet 10 mg	Oral	APO-LEFLUNOMIDE	4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together
Leflunomide	Tablet 20 mg	Oral	APO-LEFLUNOMIDE	4 months stock by reference to usual demand of both Leflunomide APOTEX and APO-LEFLUNOMIDE added together

20 Schedule 1 (table)

Omit:

Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	Oral	ARX-LERCANIDIPINE	6 months stock by reference to usual demand of both Lercanidipine APOTEX and ARX-LERCANIDIPINE added together

insert:

Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	Oral	ARX-LERCANIDIPINE	6 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026

21 Schedule 1 (table)

Omit:

Letrozole	Tablet 2.5 mg	Oral	ARX-LETROZOLE	4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together

22 Schedule 1 (table)

Omit:

Levetiracetam	Tablet 1 g	Oral	Levetiracetam Viatris	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together

23 Schedule 1 (table)

After:

Levetiracetam	Tablet 1 g	Oral	LEVETIRACETAM-WGR	6 months stock by reference to usual demand

insert:

Levetiracetam	Tablet 500 mg	Oral	Levetiracetam Viatris	4 months stock by reference to usual demand of both Levetiracetam Mylan and Levetiracetam Viatris added together

24 Schedule 1 (table)

Omit:

Levetiracetam	Tablet 250 mg	Oral	Levetiracetam Viatris	after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together
Levetiracetam	Tablet 500 mg	Oral	Levetiracetam Mylan	between 1 July 2026 to 30 September 2026—0 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026

25 Schedule 1 (table)

Omit:

Macrogol 3350	Sachets containing powder for oral solution 13.125 g with electroylytes, 30	Oral	Chemists' Own Constipation Relief with Electrolytes	4 months stock by reference to usual demand of both Chemists' Own Macrogol with Electrolytes and Chemists' Own Constipation Relief with Electrolytes added together

26 Schedule 1 (table)

Omit:

Modafinil	Tablet 100 mg	Oral	Modafinil Viatris	after 28 February 2025—4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral	APX-Montelukast	4 months stock by reference to usual demand of both Montelukast APOTEX and APX-Montelukast added together
Montelukast	Tablet, chewable, 4 mg (as sodium)	Oral	Montelukast Viatris	after 31 July 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together
Montelukast	Tablet, chewable, 5 mg (as sodium)	Oral	Montelukast Viatris	after 31 August 2025—4 months stock by reference to usual demand of both Montelukast Viatris and Montelukast Mylan added together
Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	ARX-MYCOPHENOLATE	4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together

Authorised Version F2026L01323 registered 30/09/2026

27 Schedule 1 (table)

Omit:

Naloxone	Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule	Injection	NARCAN	(a) between 1 July 2026 and 30 September 2026—560 packs of a pack quantity of 10 (b) after 30 September 2026—4 months stock by reference to usual demand

insert:

Naloxone	Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule	Injection	NARCAN	4 months stock by reference to usual demand

28 Schedule 1 (table)

Omit:

Octreotide	Injection 50 micrograms (as acetate) in 1 mL	Injection	Octreotide GH	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand
Octreotide	Injection 50 micrograms (as acetate) in 1 mL	Injection	Octreotide (SUN)	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand
Octreotide	Injection 50 micrograms (as acetate) in 1 mL	Injection	Sandostatin 0.05	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand
Octreotide	Injection 100 micrograms (as acetate) in 1 mL	Injection	Octreotide GH	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand
Octreotide	Injection 100 micrograms (as acetate) in 1 mL	Injection	Octreotide (SUN)	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand
Octreotide	Injection 100 micrograms (as acetate) in 1 mL	Injection	Sandostatin 0.1	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026

29 Schedule 1 (table)

Omit:

Olanzapine	Tablet 2.5 mg	Oral	APO-OLANZAPINE	6 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

insert:

Olanzapine	Tablet 2.5 mg	Oral	APO-OLANZAPINE	6 months stock by reference to usual demand

30 Schedule 1 (table)

Omit:

Olanzapine	Tablet 5 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

31 Schedule 1 (table)

Omit:

Olanzapine	Tablet 7.5 mg	Oral	APO-OLANZAPINE	4 months stock by reference to usual demand of both Olanzapine APOTEX and APO-OLANZAPINE added together

32 Schedule 1 (table)

Omit:

Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate)	Oral	APO-OLMESARTAN/AMLODIPINE 20/5	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 20/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 20/5 mg added together

33 Schedule 1 (table)

Omit:

Olmesartan with amlodipine	Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate)	Oral	APO-OLMESARTAN/AMLODIPINE 40/5	4 months stock by reference to usual demand of both Olmesartan/Amlodipine 40/5 APOTEX and APO-OLMESARTAN/AMLODIPINE 40/5 mg added together

Authorised Version F2026L01323 registered 30/09/2026

34 Schedule 1 (table)

Omit:

Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	Ondansetron ODT Viatris	after 30 September 2025—6 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	Ondansetron ODT Viatris	after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together

35 Schedule 1 (table)

Omit:

Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viatris	after 31 May 2025—6 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together

insert:

Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viatris	6 months stock by reference to usual demand

36 Schedule 1 (table)

Omit:

Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viatris	after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together

37 Schedule 1 (table)

Omit:

Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together

Authorised Version F2026L01323 registered 30/09/2026

insert:

Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand

38 Schedule 1 (table)

Omit:

Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand of both Pantoprazole APOTEX and APX-PANTOPRAZOLE added together

insert:

Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	APX-PANTOPRAZOLE	6 months stock by reference to usual demand

39 Schedule 1 (table)

After:

Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Sozol	5.5 months stock by reference to usual demand

insert:

Paraffin	Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g	Application to the eye	Poly Visc	Between 1 October 2026 and 28 February 2027—0 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026

40 Schedule 1 (table)

Omit:

Pioglitazone	Tablet 15 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together

41 Schedule 1 (table)

Omit:

Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 30 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	APOTEX-Pioglitazone	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together

42 Schedule 1 (table)

Omit:

Quetiapine	Tablet 100 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together

Authorised Version F2026L01323 registered 30/09/2026

Quetiapine	Tablet 200 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quetiapine	Tablet 25 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together
Quetiapine	Tablet 300 mg (as fumarate)	Oral	APX-QUETIAPINE	4 months stock by reference to usual demand of both Quetiapine APOTEX and APX-QUETIAPINE added together

43 Schedule 1 (table)

Omit:

Ramipril	Tablet 1.25 mg	Oral	Ramipril Viatris	(a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25 (b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together

insert:

Ramipril	Tablet 1.25 mg	Oral	Ramipril Viatris	3 months stock by reference to usual demand

44 Schedule 1 (table)

Omit:

Ramipril	Tablet 10 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together
Ramipril	Tablet 2.5 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together

Authorised Version F2026L01323 registered 30/09/2026

Ramipril	Tablet 5 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 5 added together

insert:

Ramipril	Tablet 10 mg	Oral	Ramipril Viatris	6 months stock by reference to usual demand
Ramipril	Tablet 2.5 mg	Oral	Ramipril Viatris	6 months stock by reference to usual demand
Ramipril	Tablet 5 mg	Oral	Ramipril Viatris	6 months stock by reference to usual demand

45 Schedule 1 (table)

Omit:

Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	APO-RIZATRIPTAN ODT	4 months stock by reference to usual demand of both Rizatriptan ODT APOTEX and APO-RIZATRIPTAN ODT added together

46 Schedule 1 (table)

Omit:

Rosuvastatin	Tablet 10 mg (as calcium)	Oral	APO-Rosuvastatin	6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-Rosuvastatin added together
Rosuvastatin	Tablet 20 mg (as calcium)	Oral	APO-ROSUVASTATIN	4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin	Tablet 40 mg (as calcium)	Oral	APO-ROSUVASTATIN	4 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	APO-ROSUVASTATIN	6 months stock by reference to usual demand of both Rosuvastatin APOTEX and APO-ROSUVASTATIN added together

Authorised Version F2026L01323 registered 30/09/2026

insert:

Rosuvastatin	Tablet 10 mg (as calcium)	Oral	APO-ROSUVASTATIN	6 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	APO-ROSUVASTATIN	6 months stock by reference to usual demand

47 Schedule 1 (table)

Omit:

Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Salbutamol Cipla	between 1 April 2026 to 30 September 2026—0 months stock by reference to usual demand

48 Schedule 1 (table)

Omit:

Sevelamer	Tablet containing sevelamer carbonate 800 mg	Oral	ARX-SEVELAMER	4 months stock by reference to usual demand of both Sevelamer Apotex and ARX-SEVELAMER added together

49 Schedule 1 (table)

After:

Sertraline	Tablet 100 mg (as hydrochloride)	Oral	Sertraline generichealth	between 1 September 2026 to 31 December 2026—0 months stock by reference to usual demand

insert:

Sevelamer	Tablet containing sevelamer carbonate 800 mg	Oral	Sevelamer Lupin	between 1 October 2026 to 30 November 2026—0 months stock by reference to usual demand

50 Schedule 1 (table)

Omit:

Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir ARX	4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together

Authorised Version F2026L01323 registered 30/09/2026

51 Schedule 1 (table)

Omit:

Vancomycin	Powder for injection 1 g (1,000,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together

52 Schedule 1 (table)

Omit:

Vancomycin	Powder for injection 500 mg (500,000 I.U.) (as hydrochloride)	Injection	Vancomycin Viatris	4 months stock by reference to usual demand of both Vancomycin Viatris and Vancomycin Alphapharm added together

53 Schedule 1 (table)

Omit:

Vincristine	I.V. injection containing vincristine sulfate 1 mg in 1 mL	Injection	DBL Vincristine Sulfate	between 1 April 2026 to 30 September 2026—4 months stock by reference to usual demand

Authorised Version F2026L01323 registered 30/09/2026